News | August 17, 2012

Xeridiem Designs Implantable Biopolymer Delivery Device to Treat Dilated Cardiomyopathy

Development services aids LoneStar Heart Inc. with new heart failure treatment

August 17, 2012 —Xeridiem, a vertically integrated OEM that designs, develops and manufactures complex single-use medical devices, announced it will provide LoneStar Heart Inc. with design and development services for the minimally invasive delivery system for Algisyl-LVR, an implantable biopolymer for the treatment of dilated cardiomyopathy.

LoneStar Heart is developing a trio of technologies with the potential to restore the heart wall structure and prevent or reverse the progression of advanced heart failure. "This development collaboration will allow LoneStar Heart to focus on their core expertise, which is further developing their Algisyl-LVR technology while relying on Xeridiem for the engineering and design control infrastructure. Essentially Xeridiem will be acting as LoneStar Heart's development team," said Joseph Lee, president of Xeridiem.

Xeridiem designs, develops and manufactures single-use medical devices focused in gastroenterology, cardiology and urology for established healthcare companies and venture-backed entrepreneurs. Since 1986, Xeridiem, as a silent partner, has enabled major medical device companies and venture-backed entrepreneurs to deliver more than 22 million medical devices used worldwide.

LoneStar Heart Inc. is developing cardiac restorative therapies for patients with heart failure that harness the heart's ability to repair itself. Based on its integrated cardiomechanical and biomolecular technologies, the privately held company is advancing a broad portfolio of products to restore the failing heart's structure and function in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. These products include Algisyl-LVR, cardiac stem-cell modulators, and cellular and genetic therapies delivered as standalone treatments, or in combination with the company's proprietary biopolymer matrix system.

For more information: www.xeridiem.com

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Overlay Init